Join collection
Hello, welcome to our official website!
科技赋能保险业—区块链助力互联网保险
2019-01-12

  保险行业的发展离不开科技的助力,本周将着重探讨如何运用区块链技术促进保险业发展。当前保险行业的痛点主要集中于安全性、信息不对称、效率低下。客户与保险公司之间的信任问题一直是制约保险行业发展的重要问题。客户信息容易被泄露,还有可能被篡改,赔付过程中可能存在重复交易或者可疑交易。客户利用信息不对称而存在骗保现象。传统保险赔付过程中有大量的人工操作环节,影响了赔付效率。

  区块链,不仅是一种技术,更是一种管理理念,核心是解决个体与集体利益的协调与管理,实现一种更加公正和**的管理,因此,其对人类社会发展与进步的意义重大,时间将证明这一点。

  保险是区块链技术应用的典型场景,能够有效解决保险经营过程中的“难点”和“痛点”,同时,能够催生出全新的商业模式。引入区块链技术之后,可以提升保险业务的安全性、缓解保险业务的信息不对称、基于智能合约有助于提升保险行业的效率。

filename


  例如保险的“**性难题”,即在保险经营过程中,面临的一个突出问题是保险欺诈,而保险欺诈往往都是在“保险标的”和“保险期限”的**性上做文章,从标的的**性看,不是“冒名顶替”,就是“张冠李戴”,这种情况*为突出的是养老保险的冒领问题。数据显示,仅是2013年,我国社保基金冒领人数达到35000人,冒领金额达到1.27亿元,为此社会还需要付出额外的大量的追讨成本。从时间**性看,就是“先出险,后投保”,而区块链技术为解决保险经营的“**性难题”提供了可能。

  现代保险的本质是一种互助制度,互助就是“一人为大家,大家为一人”,其核心是协调和处理个体与集体的关系,同时,信用是这种关系处理的基础。由此可见,保险与区块链之间有着一种“基因性”联系,因此,保险是区块链应用的典型场景。同时,面向未来,区块链将更加深刻和广泛地重构保险业。

  从区块链的特点,相互保险是一个典型的应用场景,传统的商业保险一般采取“前信任模式”,即客户先交保费,出险后按照条件进行赔付。而相互保险公司应采用的“后信任模式”,但这种“后信任模式”在实际工作中往往面临信用风险,难以逾越。利用区块链的“全网共识”机制和“不可抵赖”功能,结合互联网和大数据等技术,能够实现对信用的重构,构建一个可靠安全的信任体系,进而建立一个更加公平、透明、安全和**的互助机制,打造真正的相互保险2.0时代。面向未来,基于区块链等相关科技的有效运用,相互保险公司可能*终演进为“机器保险公司”。公司的运营,不再依赖第三方的存在,完全由系统自动完成,运营平台赋予每一个个体以“金融”属性,构成典型的“自保险”形态,从而开拓相互保险的全新时期,进入“自保险”时代。

filename

  国际上,全球首家P2P保险”平台Lemonade、基于以太坊的P2P失业保险平台Dynamis以及全球五大保险巨头联合发起的B3i平台。这家打出“全球首家P2P保险”的创业公司成立于2015年,位于纽约州。主要从事财产和意外伤害保险,通过区块链技术,信息不会丢失,公司选择用智能合约自动理赔,减少过程中的繁琐认证过程,*快可以三分钟获得赔付。目前Lemonade获得红杉资本有史以来*大规模种子轮融资,金额高达1300万美元,投资方还包括软银、Google Venture。

  我国保险业积极开展区块链技术应用,中国保险业对区块链技术的探索可以追溯至2016年,阳光保险、蚂蚁金服、人保财险、上海保险交易所、中国人寿等来自国有保险公司、大型商业保险公司,乃至年轻的小型保险公司,都陆续投入对区块链的研究。中国人保已经开展了保险营销和养殖保险等领域的应用,上海保交所开展了地震保险的“共保体 + 区块链”尝试,上海保监局利用区块链技术,开展再保险管理平台探索。面向未来,区块链的保险应用前景广阔。

  从应用落地的节奏来看,中美的商业保险公司、小型保险公司相较于大型国有保险企业,探索步伐来得更快。

  由硅谷洞察旗下硅谷洞察研究院发布《区块链中美发展白皮书》中提到金融保险领域的区块链创业公司数量和获得的融资额*多。硅谷洞察研究院对全球*权威的科技创新公司数据库Crunchbase的数据进行分析后发现,在数据库收录的与这五大行业相关的1416个区块链项目中,服务于金融保险行业的区块链初创项目为1223个,占总数的86.5%。而且在披露融资数据的371家区块链初创企业中,总融资额的96%是由金融保险领域的区块链创业公司获得。

filename

  区块链还能够为提供保险的运营效率,改善客户体验提出可能,区块链中有一项核心技术是智能合约,它能够大大提高保险合同执行的效率,特别是在理赔环节,通过智能合约技术,能够使保险理赔更加规范和刚性,提高客户体验水平。同时,区块链的分布式技术,能够保险理赔数据的交换提供更加便捷的方式,一方面是避免单证收集与交换的工作,另一方面也能够避免道德风险导致的骗赔。

  同时当前区块链技术落地保险业依然存在诸多难点,比如在技术层面存在扩展性问题、安全问题等,在非技术层面面临着对参与者总体管理能力、观念的挑战、对问责、责权分配的挑战、跟现有规则的冲突等一系列矛盾。

  如何更好的利用区块链技术解决当前保险行业的痛点,如何更好的让区块链技术落地保险业?启明星在线将在继续为您带来*新的资讯。

暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online